StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for Rein Therapeutics

Rein Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Rein Therapeutics figures

See a number that looks wrong?